Jager G, Hofler G, Linkesch W, Neumeister P (2004) Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica 89(4):ECR01...
Described is the therapy-related AML (acute myelogenetic leukemia)/MDS (myelo-dysplasia syndrome), which is manifested after various treatments of low-grade B-cell lymphoma and has strongly attracted attention because of the markedly improved prognosis due to recent advantages of the therapy for the...
The role of mesenchymal stromal cells (MSCs) in the pathogenesis of myelodysplastic syndromes (MDS) has been increasingly addressed, but has yet to be clearly elucidated. In this investigation, we found that MDS cells proliferated to a greater extent on MDS-derived MSCs compared to normal MSCs....
42、low cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108:10371044.van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1_risk myelodysplastic syndromes by flow cytometry. Blood,...
CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplactics Syndromes (MDS) CD38 expression on CD34+ Bone Marrow Cells (BM) as a tool in low grade Myelodysplactics Syndromes (MDS)Stroke associated with antiphospholipid syndrome ... R Siguenza,MH Banas,I ...
Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome. Minimal tumor lysis syndrome was observed with venetoclax combined with hypomethylating agents in patients with myelodysplastic syndrome. Investigators found that venetocla...
Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found. Results from a recent study showed that, in patients with myelodysplastic syndrome (MDS), tobacco smoking can influence the disease’s multistep molecular pathogenesis through g...
Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.
Myelodysplastic syndrome (MDS) is a very heterogeneous clonal disorder. Patients with “higher-risk” MDS, defined by specific recurrent genetic abnormalities, have a poor prognosis because of a high risk of progression to secondary acute myeloid leukemia with low chemosensitivity. Allogeneic hematopoietic...
Findings from several large phase 3 studies along with continued development of emerging therapies promise to alter the treatment landscape for patients with myelodysplastic syndromes. Rami Komrokji, MD Traditionally, the treatment backbone for patients with myelodysplastic syndromes (MDS) has been ...